MET gain in diffuse astrocytomas is associated with poorer outcome

Brain Pathology

Volumn 23, Issue 1, 2013, Pages 13-18

  Pierscianek, Daniela ^a   Kim, Young Ho ^a   Motomura, Kazuya ^a   Mittelbronn, Michel ^b   Paulus, Werner ^c   Brokinkel, Benjamin ^c,d   Keyvani, Kathy ^e   Wrede, Karsten ^f   Nakazato, Yoichi ^g   Tanaka, Yuko ^g   Mariani, Luigi ^h   Vital, Anne ⁱ   Sure, Ulrich ^f   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Institute of Neuropathology   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e Institute of Pathology and Neuropathology   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g GUNMA UNIVERSITY   (Japan)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

diffuse astrocytoma; MET; primary glioblastoma; secondary glioblastoma

Indexed keywords

SCATTER FACTOR RECEPTOR;

ADULT; ARTICLE; ASTROCYTOMA; CANCER DIAGNOSIS; CANCER SURVIVAL; FEMALE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 7; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; PROTO-ONCOGENE PROTEINS C-MET; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84870865781     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2012.00609.x     Document Type: Article

References (51)

1. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
2. Abounader R, Laterra J, (2005) Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7: 436-451. (Pubitemid 41555616)
3. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, et al, (2002) c-Met expression in gastric cancer with liver metastasis. Oncology 63: 286-296. (Pubitemid 36151324)
4. Arslantas A, Artan S, Oner U, Muslumanoglu MH, Ozdemir M, Durmaz R, et al, (2007) Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res 13: 39-46. (Pubitemid 46883545)
5. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF, (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925. (Pubitemid 37493640)
6. Bourne TD, Schiff D, (2010) Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 6: 695-701.
7. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al, (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27: 1667-1674.
8. Cheng TL, Chang MY, Huang SY, Sheu CC, Kao EL, Cheng YJ, Chong IW, (2005) Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 128: 1453-1460.
9. Gherardi E, Birchmeier W, Birchmeier C, Vande WG, (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89-103.
10. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, et al, (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29: 4789-4795.
11. Hirose Y, Kojima M, Sagoh M, Murakami H, Yoshida K, Shimazaki K, Kawase T, (1998) Immunohistochemical examination of c-Met protein expression in astrocytic tumors. Acta Neuropathol 95: 345-351. (Pubitemid 28142542)
12. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al, (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75: 1560-1566.
13. Idbaih A, Carvalho SR, Criniere E, Marie Y, Carpentier C, Boisselier B, et al, (2008) Genomic changes in progression of low-grade gliomas. J Neurooncol 90: 133-140.
14. Ishii N, Tada M, Hamou MF, Janzer RC, Meagher-Villemure K, Wiestler OD, et al, (1999) Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 18: 5870-5878. (Pubitemid 29520443)
15. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, et al, (2006) Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66: 352-361. (Pubitemid 43166042)
16. Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, et al, (2011) Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene, in press.
17. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, et al, (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177: 2708-2714.
18. Kraus JA, Bolln C, Wolf HK, Neumann J, Kindermann D, Fimmers R, et al, (1994) TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 10: 143-149. (Pubitemid 24155986)
19. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, et al, (2009) Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 15: 5714-5723.
20. Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG, (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61: 7683-7688. (Pubitemid 32995066)
21. Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, et al, (2009) EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 8: 1751-1760.
22. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, et al, (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25: 1517-1524.
23. Liu W, Fu Y, Xu S, Ding F, Zhao G, Zhang K, et al, (2011) c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme. J Clin Neurosci 18: 119-121.
24. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al, (1998) Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 62: 768-775. (Pubitemid 28194317)
25. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, (eds) (2007) WHO Classification of Tumours of the Central Nervous System. IARC: Lyon.
26. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, et al, (2008) Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47: 1025-1037.
27. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al, (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12: 6144-6152. (Pubitemid 44703780)
28. Moriyama T, Kataoka H, Koono M, Wakisaka S, (1999) Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). Int J Mol Med 3: 531-536.
29. Morohara K, Nakao K, Tajima Y, Nishino N, Yamazaki K, Kaetsu T, et al, (2005) Analysis by comparative genomic hybridization of gastric cancer with peritoneal dissemination and/or positive peritoneal cytology. Cancer Genet Cytogenet 161: 57-62. (Pubitemid 41096051)
30. Nabeshima K, Shimao Y, Sato S, Kataoka H, Moriyama T, Kawano H, et al, (1997) Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 31: 436-443. (Pubitemid 27505360)
31. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K, (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158: 1253-1262. (Pubitemid 32281289)
32. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H, (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007.
33. Ohgaki H, Kleihues P, (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28: 177-183.
34. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al, (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899. (Pubitemid 39330996)
35. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al, (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade astrocytomas and oligodendrogliomas. Acta Neuropathol 108: 49-56. (Pubitemid 38961073)
36. Organ SL, Tsao MS, (2011) An overview of the c-MET signaling pathway. Ther Adv Med Oncol 3: S7-S19.
37. Peraud A, Ansari H, Bise K, Reulen HJ, (1998) Clinical outcome of supratentorial astrocytoma WHO grade II. Acta Neurochir (Wien) 140: 1213-1222. (Pubitemid 29020984)
38. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ, (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO Grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8: 1117-1124. (Pubitemid 34517648)
39. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al, (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154.
40. Schmidt H, Taubert H, Wurl P, Kappler M, Lange H, Bartel F, et al, (2002) Gains of 12q are the most frequent genomic imbalances in adult fibrosarcoma and are correlated with a poor outcome. Genes Chromosomes Cancer 34: 69-77. (Pubitemid 34260598)
41. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al, (1999) Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18: 2343-2350. (Pubitemid 29192711)
42. Schrock E, Blume C, Meffert MC, du MS, Bersch W, Kiessling M, et al, (1996) Recurrent gain of chromosome arm 7q in low-grade astrocytic tumors studied by comparative genomic hybridization. Genes Chromosomes Cancer 15: 199-205. (Pubitemid 26115928)
43. Shafqat S, Hedley Whyte ET, Henson JW, (1999) Age-dependent rate of anaplastic transformation in low-grade astrocytoma. Neurology 52: 867-869. (Pubitemid 29120202)
44. Sharma N, Adjei AA, (2011) In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther Adv Med Oncol 3: S37-S50.
45. Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, et al, (2012) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 118: 452-460.
46. van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C, (1998) Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 64: 581-587. (Pubitemid 28204142)
47. Walter BA, Begnami M, Valera VA, Santi M, Rushing EJ, Quezado M, (2011) Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression. J Neurooncol 101: 199-206.
48. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, et al, (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3: 523-530. (Pubitemid 27211828)
49. Wiltshire RN, Herndon JE, Lloyd A, Friedman HS, Bigner DD, Bigner SH, McLendon RE, (2004) Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. J Mol Diagn 6: 166-179. (Pubitemid 39136643)
50. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O, (2012) Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. Mod Pathol 25: 122-130.
51. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al, (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.